Utomilumab ELISA Kit (KDG11002)

Colorimetric

Plasma, Serum

Quantitative

0.31-5 μg/mL

0.156 μg/ml

CV<20%

80-120%

2-8 ℃

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Utomilumab is the proposed non-proprietary name for PF-05082566, an investigational immunotherapy and a fully human IgG2 agonist monoclonal antibody (mAb) that binds to the extracellular domain of human 4-1BB/CD137 with high affinity and specificity. It is developed by Pfizer to treat advanced cancers either alone or in combination with other therapies. When utomilumab is injected into a person's bloodstream, it binds to 4-1BB on immune cells and stimulates them. At present, the approval of the monoclonal antibody has not been disclosed in the relevant authoritative drug approval agency, such as the European Medicines Agency and the U.S. Food and Drug Administration (FDA).